[1] 许迎辉, 李响, 韩玉英.噻托溴铵联合沙美特罗/丙酸氟替卡松吸入治疗对慢性阻塞性肺疾病病人肺功能的影响[J].中国医药导报, 2016, 13(3):146.
[2] 向敏.噻托溴铵联合沙美特罗替卡松吸入对中重度稳定期COPD病人气道功能和气道炎症的影响[J].海南医学院学报, 2016, 22(23):2814.
[3] 王新杰.COPD急性加重期和稳定期病人的肺功能评估及其与血清促炎因子、趋化因子的相关性[J].海南医学院学报, 2016, 22(21):2629.
[4] 张聆, 王孝明, 田云, 等.噻托溴铵与沙美特罗氟替卡松联用对COPD病人的疗效及细胞免疫功能的影响[J].西部医学, 2016, 28(7):976. doi: 10.3969/j.issn.1672-3511.2016.07.021
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志, 2013, 36(4):484.
[6] CASANOVA C, MARIN JM, MARTINEZ-GONZALEZ C, et al.Differential effect of modified medical research council dyspnea, COPD assessment test, and clinical COPD questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD[J].Chest, 2015,148(1):159.
[7] 李静姿, 周颖, 崔一民.慢性阻塞性肺疾病三联用药定量吸入剂的研究现状[J].中国临床药理学杂志, 2017, 33(21):2199.
[8] CUI S, ZHU H.Efficacy and safety of long-term nebulized budesonide inhalation in elderly COPD patients[J].Chest, 2016,149(4):A391. doi: 10.1016/j.chest.2016.02.406
[9] DHILLON S.Tiotropium/olodaterol:a review in COPD[J].Drugs, 2016, 76(1):135. doi: 10.1007/s40265-015-0527-2
[10] 路宏燕, 付臣.噻托溴铵联合沙美特罗替卡松治疗中重度COPD的临床观察[J].中国药房, 2016, 27(35):4971. doi: 10.6039/j.issn.1001-0408.2016.35.24
[11] 黄宁侠, 刘英锋, 宋新亮.噻托溴铵联合布地奈德/福莫特罗吸入对老年重度COPD病人呼吸功能和运动耐力的影响[J].西北国防医学杂志, 2016, 38(3):144.
[12] AJQORTA J, ANDRADE L, MEDINA M, et al.Pharmacokinetic bioequivalence of two inhaled tiotropium bromide formulations in healthy volunteers[J].Clin Drug Investig, 2016, 36(9):753. doi: 10.1007/s40261-016-0441-8
[13] DAUBIN C, VALETTE X, THIOLLIÈRE F, et al.Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU:a randomized multicenter study[J].Intensive Care Med, 2018, 44(4):1.
[14] 刘剑臻, 杜秀芳.COPD急性加重期病人血清CRP和PCT含量与全身炎症反应程度的相关性分析[J].海南医学院学报, 2017, 23(5):620.
[15] ZHANG M, LI Y, YANG X, et al.Serum cystatin C as an inflammatory marker in exacerbated and convalescent COPD patients[J].Inflammation, 2016, 39(2):625. doi: 10.1007/s10753-015-0287-x